Received May 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 45YF9 | — |
Inadvertent administration of a pediatric dose to an adult; Inadvertent administration of a pediatric dose to an adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 50-year-old female patient who received HAV (Havrix pediatric) (batch number 45YF9, expiry date 2028) for prophylaxis. On 13-MAY-2026, the patient received the 2nd dose of Havrix pediatric. On 13-MAY-2026, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: Inadvertent administration of a pediatric dose to an adult) and accidental underdose (Verbatim: Inadvertent administration of a pediatric dose to an adult). The outcome of the adult use of a child product and accidental underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-MAY-2026 The reporter stated that the patient had received the pediatric dose for her second dose and was concerned about proceeding with the adult dose. She worried that she might receive too much of the vaccine and potentially overload her body.